Search PubMed⌕ Search

Biomedical subjects

Z Y Lu

Publications and source records attributed to Z Y Lu.

63 records · Page 4Linked to original sources
PubMed1989

[Tubal anastomosis for reversal of sterilization with microsurgical technic in 246 women].

Tubal anastomosis for reversal of sterilization was performed with microsurgical technique in 246 women, from January 1985 to June 1987. The operation time after tubal sterilization averaged 43.5 months. The patients (99.6%) were followed-up for 3-33 months. Intrauterine pregnancies occurred in 178 cases, the rate being 72.4%. The factors which influence success rate are the tubal length after anastomosis and the mode of original tubal ligation. Postoperative instillation of fluids into fallopian tubes should be performed early to prevent adhesions and early intercourse should also be encouraged.

Adult↗
PubMed1989

[Experiences with 184 cases of chronic hemodialysis].

From 14 years' experience of 184 cases of chronic hemodialysis for ESRD, we confirmed that dialysis should begin when Ccr is 5-10 ml/min, and in individualized treatment with dialysis, prevention and treatment of renal osteodystrophy is important in patients undergoing maintenance hemodialysis. Suitable dialysis and rational nutrition can improve renal anemia. Complications decreased significantly in the recent 4-5 years, and 1-year, 5-year and 10-year survival rates were 90.9%, 77.8% and 58.8% respectively.

Adult↗
PubMedDate not supplied

Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.

When bone-marrow cells from patients with multiple myeloma (MM) were seeded in short-term cultures, a spontaneous proliferation of the myeloma cells occurred for most of the patients with active disease and proliferating myeloma cells in vivo. In all cases, this spontaneous proliferation was inhibited by anti-IL-6 monoclonal antibodies (mabs). Moreover, myeloma cell lines, completely dependent upon exogenous IL-6 for their growth, could be reproducibly established by initially stimulating the myeloma cells with both IL-6 and GM-CSF. These results demonstrate that IL-6 is a major paracrine myeloma-cell growth factor in vitro. High serum IL-6 levels were observed in MM patients with active disease, especially patients with terminal disease. High IL-6 mRNA levels were found in bone-marrow cells of MM patients, mainly in myeloid and monocytic cells, in vivo. The myeloma cells did not express IL-6 mRNA. Injection of anti-IL-6 mabs to MM patients with terminal disease and extramedullary proliferation, completely blocked the myeloma-cell proliferation in vivo and completely inhibited the serum IL-6 bioactivity and the serum CRP levels. One patient with plasma cell leukemia and hypercalcemia was treated for two months with anti-IL-6 mabs and maintain in remission for 2 months without major side effects. Interestingly, the serum calcium levels also decreased in these patients. All these results show that IL-6 is the main cytokine responsible not only for the myeloma-cell proliferation in vivo, but presumably also for the large bone resorption processes observed in human MM.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMedDate not supplied

Epitope analysis of human IL-6 receptor gp80 molecule with monoclonal antibodies.

Gp80 human IL-6R was studied using 7 murine mAb (M37, M91, M113, M139, M164, M182 and M195) obtained after fusion of splenocytes of Balb/c mice immunised with a mixture of recombinant IL-6 receptor (rIL-6R) and cells from 2 cell lines expressing IL-6R. These were U266, which is IL-6 independent and XG-1 which is IL-6-dependent. In ELISA the 7 mAb reacted against the rIL-6R and against the natural soluble form found in plasma (nIL-6R), which both lack transmembrane and cytoplasmic domains. However, M195 reacted less with the natural than with the recombinant soluble IL-6R. Using FACS analysis, the 7 mAb were shown to bind to U266 cells but not to the Namalva cell line which is deprived of IL-6R. This showed that they all recognised the membrane form of the IL-6R. Three of the anti-IL-6R mAb reacted with rIL-6R by Western blotting. Four different epitopes of the molecule were identified, either by cross-blocking experiments of mAb binding to IL6R in ELISA or by the biosensor Biacore technology. A group of 4 mAb (M37, M113, M139 and M164) and another mAb (M195) identified 2 different epitopes involved in IL-6 binding. These antibodies were able to inhibit the binding of IL-6 to IL-6R and the proliferation of the IL-6-dependent XG-1 cell line. M91 and M182 recognized 2 other epitopes that were not involved in IL-6 binding. As expected, M91 did not inhibit XG-1 proliferation; in contrast, M182 interfered with the proliferative response of the XG-1 cell line.(ABSTRACT TRUNCATED AT 250 WORDS)

Antibodies, Monoclonal↗